Nostrum Pharmaceuticals
Basingstoke
United Kingdom
10 articles about Nostrum Pharmaceuticals
-
J&J indicated it will soon release Phase III data and could file for Emergency Use Authorization with the U.S. Food and Drug Administration by the end of the month.
-
The AP in a recent report notes that drug price increases “slowed somewhat and were not quite as steep as in past years.” But overall, there has been no “massive” drug price cuts.
-
A study published in the Annals of Internal Medicine highlights some of the problems that drug shortages bring to the healthcare system, including a rise in prices. The research, as highlighted by Business Insider, examined the prices of 917 drugs that were in shortage between 2015 and 2016.
-
Nostrum Pharmaceuticals Announcement Of Its Acquisition Of Sun Pharma's Bryan, Ohio Facility Along With Related Products And Employees
12/15/2015
-
Nostrum Pharmaceuticals Licenses Clinical Development and Worldwide Commercialization Rights From IMTECH, India for Novel, Next-Generation Thrombolytics With Clot Specific Activation and Re-occlusion Prevention Properties
11/29/2010
-
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
2/24/2009
-
Nostrum Pharmaceuticals Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
4/22/2008
-
Synovics Pharmaceuticals, Inc. Announces the Settlement of all Legal Proceedings with Nostrum Pharmaceuticals., Dr. Nirmal Mulye and Anil Anand
8/7/2007
-
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From Institute of Microbial Technology (IMTECH) For Clinical Development Of A Novel Clot Busting Therapeutic Protein
7/28/2006
-
Nostrum Pharmaceuticals Confident Regarding Outcome Of Shire Laboratories' Carbamazepine ER Litigation
7/27/2005